BioNTech SE (NASDAQ:BNTX) shares are down during Tuesday’s premarket session as the company announced plans for its co-founders to transition into a new venture focused on next-generation mRNA innovations.
With both companies focusing on their respective strategic priorities, BioNTech expects to maximize value for patients and shareholders alike.
Unexpected Transition
Co-founders Ugur Sahin and Özlem Türeci will move to lead their new company by the end of 2026, with BioNTech’s Supervisory Board initiating an executive search for successors.
The new venture aims to advance mRNA technologies, while BioNTech will sharpen its focus on its existing pipeline, which includes 15 ongoing Phase 3 clinical trials in oncology by year-end.
2026 will also be the first year in which BioNTech expects multiple late-stage data readouts across major cancer types. The clinical trials and resulting data will inform regulatory and launch plans.
BNTX Earnings Beat Estimates
BioNTech reported:
- Fourth-quarter loss of 38 cents (33 cents in euros), beating the consensus of a loss of 47 cents.
- Sales of $1.06 billion (907.4 million euros), beating the consensus of $889.48 million.
- A quarterly year-on-year sales decrease was primarily driven by reduced market demand of the company’s COVID-19 vaccines.
- Lower COVID-19 vaccine revenue expectations in 2026 compared to 2025, driven by declines in both the European and U.S. markets.
- Fiscal 2026 sales in the range of $2.33 billion-$2.68 billion (between 2-2.3 billion euros) compared to the consensus of $3.12 billion.
BioNTech Prior Key Developments
In February, the company filed a patent infringement lawsuit against Moderna Inc. (NASDAQ:MRNA), alleging that Moderna’s next-generation COVID-19 vaccine, mNEXSPIKE, relies on proprietary technology developed and patented by BioNTech.
In December, BioNTech and its partner Bristol Myers Squibb & Co. (NYSE:BMY) shared the first interim data from a global randomized Phase 2 trial of pumitamig (BNT327/BMS986545) plus chemotherapy for locally advanced/metastatic triple-negative breast cancer (TNBC) irrespective of PD-L1 expression levels.
In November, Pfizer Inc. (NYSE:PFE) said it is offloading its remaining stake in its COVID-19 vaccine partner.
BioNTech Technical Analysis
Currently, BioNTech is trading 18% below its 100-day simple moving average (SMA) and 20.8% below its 20-day SMA, indicating a bearish trend.
Shares have decreased 3.03% over the past 12 months and are positioned closer to their 52-week lows than highs.
The RSI is at 41.49, which is considered neutral territory, suggesting that the stock is neither overbought nor oversold. Meanwhile, the MACD is at -1.4056, below its signal line at -0.3937, indicating bearish pressure on the stock.
The combination of neutral RSI and bearish MACD suggests mixed momentum for BioNTech.
- Key Resistance: $101.50
- Key Support: $81.00
Benzinga Edge Rankings
Below is the Benzinga Edge scorecard for BioNTech SE American Depositary Share, highlighting its strengths and weaknesses compared to the broader market:
- Momentum: Weak (Score: 19.82) — Stock is underperforming the broader market.
The Verdict: BioNTech SE American Depositary Share’s Benzinga Edge signal reveals a classic ‘High-Flyer’ setup. While the Momentum (19.82) confirms the weak trend, the company’s strategic pivot may provide future opportunities for growth.
BNTX Price Action: BioNTech shares were down 14.25% at $87.60 during premarket trading on Tuesday, according to Benzinga Pro data.
Image via Shutterstock
Recent Comments